Monthly Archives: February 2019

Marker Therapeutics announces updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.

Marker Therapeutics would like to congratulate Scientific Advisory Board Member, Helen E. Heslop, MD, DSc (Hon), on receiving the ASBMT Lifetime Achievement Award.

President and CEO, Peter L. Hoang, and Chief Development Officer, Dr. Juan Vera, will be presenting at the CAR-TCR Summit Europe.

Marker Therapeutics has formally relocated their corporate headquarters from Jacksonville, Florida to Houston, Texas. In addition, the Company has announced that it is now a resident company at Johnson & Johnson Innovation – JLABS (JLABS at TMC).

Marker Therapeutics appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development. In this role, she will be responsible for clinical development strategy, clinical study design, and medical oversight of the Company’s therapeutic product candidates. Dr. Koneru joins Marker Therapeutics from Eli Lilly and Company, where she served most recently as Associate Vice President of Immuno-Oncology.

Chief Financial Officer, Anthony H. Kim, to present a corporate overview at the upcoming BIO CEO & Investor Conference on Monday, February 11, 2019.